Endometrial Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with a specific type of uterine (endometrial) cancer, confirmed by laboratory testing of tissue, including certain subtypes such as endometrioid, serous, clear cell, carcinosarcoma, or dedifferentiated
- People whose cancer has features that mean radiation therapy to the pelvis is recommended after surgery, based on established medical guidelines — this includes factors such as tumour grade, how deeply the cancer has grown into the uterine wall, whether cancer cells were found in blood or lymph vessels, whether nearby lymph nodes were affected, whether the cervix was involved, or whether certain molecular markers associated with a poorer outlook are present
- People aged 18 years or older
- People who are able to understand and agree to participate in the trial (provide informed consent)
- People who are able to receive additional drug treatment after surgery, if the treating doctor determines this is needed, with at least a 3-week gap between any chemotherapy and radiation therapy
- People who are willing and able to complete quality-of-life questionnaires (standardised cancer and gynaecological cancer questionnaires) in an available language version
Who may not be able to join:
- People who have previously had radiation therapy to the pelvis
- People who have a medical condition that makes pelvic radiation therapy unsafe, such as an active connective tissue disorder or inflammatory bowel disease
- People who have a hip replacement that could interfere with the planning or delivery of radiation treatment
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Lara M Hathout, Rutgers University - Cancer Institute
Phone: 732-235-2465
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Incidence of Acute Grade ≥2 Gastrointestinal and Genitourinary Toxicity
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.